The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

Sarcomas are heterogeneous malignancies with limited therapeutic options and a poor prognosis. We developed an innovative immunotherapeutic agent, a first-in-class Pronectin™-based Bispecific T-Cell Engager (pAXL×CD3ε), for the targeting of AXL, a TAM family tyrosine kinase receptor highly expressed...

Full description

Bibliographic Details
Main Authors: Nicoletta Polerà, Antonia Mancuso, Caterina Riillo, Daniele Caracciolo, Stefania Signorelli, Katia Grillone, Serena Ascrizzi, Craig A. Hokanson, Francesco Conforti, Nicoletta Staropoli, Luigia Gervasi, Maria Teresa Di Martino, Mariamena Arbitrio, Giuseppe Nisticò, Roberto Crea, Pierosandro Tagliaferri, Giada Juli, Pierfrancesco Tassone
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
sarcomas
AXL
pronectins™
bispecific T-cell engager
BTCE
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/15/6/1647

Internet

https://www.mdpi.com/2072-6694/15/6/1647

Similar Items